SCHEMBL19206654

SCHEMBL19206654

COc1cncc(Cc2nc3c(Cc4ccccc4)[nH]c(-c4ccccc4)cn-3c2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 5/20 0.43
▸ CYP11B2 P19099 5/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ FYN P06241 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ USP2 O75604 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ LTB4R Q15722 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19206678 0.90 LTB4R (0.47) ALDH1A1USP2CYP1A2CYP3A4CYP2C9
SCHEMBL4547065 0.88 ALDH1A1 (0.45) KCNH2ALDH1A1USP2CYP1A2CYP3A4
SCHEMBL10012889 0.87 KDM4E (0.43) ALDH1A1USP2CYP1A2CYP3A4CYP2C9
SCHEMBL12735455 0.86 ALDH1A1 (0.43) KCNH2ALDH1A1USP2CYP1A2CYP3A4
SCHEMBL19206732 0.86 CYP11B1 (0.39) CYP11B1CYP11B2ALDH1A1USP2CYP1A2
SCHEMBL492636 0.85 LTB4R (0.41) ALDH1A1CYP2C9SMN1; SMN2KDM4ELTB4R
SCHEMBL29886558 0.85 ADORA3 (0.40) ALDH1A1USP2CYP1A2CYP3A4CYP2C9
SCHEMBL19206677 0.84 CYP1A2 (0.43) ALDH1A1USP2CYP1A2CYP3A4CYP2C9
SCHEMBL10196905 0.84 LTB4R (0.43) ALDH1A1USP2CYP1A2CYP2C9CYP2C19
SCHEMBL30110529 0.84 LTB4R (0.41) ALDH1A1USP2CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340923-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORP (US) 2025-11-06 — — US claimed
US-20210254128-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2021-08-19 — — US claimed
US-11015216-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2021-05-25 — — US claimed
US-20200263229-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-08-20 — — US claimed
US-10669568-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2020-06-02 — — US claimed
US-20190241932-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2019-08-08 — — US claimed
US-20180223330-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-08-09 — — US claimed
US-20170233789-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2017-08-17 — — US claimed
US-20250340923-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORP (US) 2025-11-06 — — US disclosed
US-12391973-B2 Substituted imidazo[1,2-α]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2025-08-19 — — US disclosed
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PROMEGA CORPORATION 2024-02-29 — — US disclosed
US-11781168-B2 Process for preparing substituted imidazo[1,2-α]pyrazines PROMEGA CORPORATION (US) 2023-10-10 — — US disclosed
US-20210254128-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2021-08-19 — — US disclosed
US-11015216-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2021-05-25 — — US disclosed
US-10669568-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2020-06-02 — — US disclosed
US-20190241932-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2019-08-08 — — US disclosed
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates PROMEGA CORPORATION (US) 2019-06-04 — — US disclosed
US-20180223330-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-08-09 — — US disclosed
US-9924073-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof PROMEGA CORPORATION (US) 2018-03-20 — — US disclosed
US-20170233789-A1 COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2017-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11781168-B2 Process for preparing substituted imidazo[1,2-α]pyrazines CYP4Z1, CYP2E1, CYP2F1 CYP11B1 58/4885CYP11B2 72/4885KCNH2 435/4885
US-20210254128-A1 COELENTERAZINE ANALOGUES AADAC, GLB1, PGLS CYP11B1 2830/4885CYP11B2 2806/4885KCNH2 1406/4885
US-20250340923-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PGLS, AADAC, GLB1 CYP11B1 2877/4885CYP11B2 2909/4885KCNH2 2862/4885
US-20190241932-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 CYP11B1 3408/4885CYP11B2 3248/4885KCNH2 1711/4885
US-11015216-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates GLB1, PGLS, AADAC CYP11B1 2319/4885CYP11B2 2429/4885KCNH2 2164/4885
US-20180223330-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 CYP11B1 3408/4885CYP11B2 3248/4885KCNH2 1711/4885
US-20170233789-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 CYP11B1 3408/4885CYP11B2 3248/4885KCNH2 1711/4885
US-20200263229-A1 COELENTERAZINE ANALOGUES AADAC, GLB1, PGLS CYP11B1 2830/4885CYP11B2 2806/4885KCNH2 1406/4885
US-10308975-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates AADAC, PGLS, GLB1 CYP11B1 2954/4885CYP11B2 2994/4885KCNH2 2855/4885
US-20240068009-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES PGLS, AADAC, GLB1 CYP11B1 2877/4885CYP11B2 2909/4885KCNH2 2862/4885
US-10669568-B2 Substituted imidazo[1,2-a]pyrazines as luciferase substrates AADAC, PGLS, GLB1 CYP11B1 2921/4885CYP11B2 2949/4885KCNH2 2886/4885
US-12391973-B2 Substituted imidazo[1,2-α]pyrazines as luciferase substrates PGLS, GLB1, AADAC CYP11B1 2902/4885CYP11B2 2997/4885KCNH2 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback